T. Rowe Price Associates’s Abiomed Inc ABMD Stock Holding History

T. Rowe Price Associates’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,398,500	Closed	-$28.3M	–	3074
2022 Q2	$28.3M	Buy	+1,398,500	New	+$377M	﹤0.01%	1066

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's ABMD Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 130,875 shares — an estimated $32.2M sold.

T. Rowe Price Associates first reported a position in ABMD in Q2 2013 and held it in 37 quarters. The position peaked at $151M in Q4 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

T. Rowe Price Associates reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
T. Rowe Price Associates sold 130,875 Abiomed Inc shares in Q4 2022, an estimated $32.2M.
T. Rowe Price Associates first reported a position in Abiomed Inc in Q2 2013 and held it in 37 quarters.
T. Rowe Price Associates's Abiomed Inc position peaked at $151M in Q4 2019.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.